Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Multicenter Study to Assess the Pharmacokinetics, Safety, and Tolerability of Immune Globulin Subcutaneous (Human) IgPro20 in IG Treatment-naïve Subjects With Primary Immunodeficiency

NCT07076446 is registered in ClinicalTrials.gov with CSL Behring as lead sponsor.

NCT NCT07076446
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07076446 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Multicenter Study to Assess the Pharmacokinetics, Safety, and Tolerability of Immune Globulin Subcutaneous (Human) IgPro20 in IG Treatment-naïve Subjects With Primary Immunodeficiency
Lead sponsor
CSL Behring
Phase
Phase 4
Overall status
Completed
Start date
July 15, 2025
Completion date
June 30, 2026
Enrollment
8 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

primary immunodeficiency